OVARIAN Non-commercial trials
Trial Study description Status
ADRAPAC/
CEEGOG OX-03
Symptomatic Ascites Drainage with a Patient-controlled Vascular Catheter
The target size of the group: 170 subjects
Ongoing
REGYS Rare gynecological sarcoma study
The target size of the group: 782 subjects
Ongoing
SOLERO/
ENGOT-OV64/NSGO-CTU
An Early Phase Randomized Trial of APX005M in BRCAwt Patients with Recurrent Ovarian Cancer
The target size of the group: 105 subjects
Under preparation
HE4-FU-OVCA/
CEEGOG OX-01
documents available here
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer
A prospective multicentre observational study
The target size of the group: 150 subjects
Enrollment closed
ATALANTE/
ENGOT-ov29/GINECO
A randomized, double blinded, phase III study of Atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and Bevacizumab
The target size of the group: 600 subjects
Enrollment closed
EXPRESSION VI/
ENGOT-ov40/NOGGO S13
Caroline meets HANNA – Holistic Analysis of longterm survivors with ovarian cancer
The target size of the group: 100-200 subjects per participating country
Closed
MITO33/
ENGOT-ov51
A Randomized phase III trial on Niraparib-TSR 042 vs physician’s choice chemotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment
The target size of the group: 427 subjects
Under preparation

 

 

CERVICAL Non-commercial trials
Trial Study description Status
CoNteSSa/NeoCon-F FIGO 2018 stage IB2(≥2cm ≤4cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa)/ Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F)
The target size of the group: 90 subjects
Under preparation

CEEGOG CX-06
Rare cervical tumour study
The target size of the group: 300+ subjects
Under preparation
SENTIX/
CEEGOG CX-01/
ENGOT-cx2
documents available here
Sentinel node in cervix cancer
A prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer
The target size of the SLN Study group: 600 subjects
The target size of the Control group: 100 subjects
Estimated enrollment period: 2016 – 2020
Enrollment closed
FERTISS/
CEEGOG CX-03/
ENGOT-cx14
documents available here
FERTIlity Sparing Surgery in cervical cancer patients outside controlled trials Closed
CERVANTES/
CEEGOG CX-05/
ENGOT-cx16
An international randomised trial of radical surgery followed by adjuvant (chemo)radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer patients
The target size of the group: 514 subjects
Under preparation
RSS-EAC-PAT/
CEEGOG CX-04
documents available here
The Risk Stratification System for endocervical adenocarcinoma based on tumor pattern and its clinical outcomes  Closed
ABRAX/
CEEGOG CX2/
ENGOT-cx3
documents available here
Oncological outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of LN positivity Closed
SALVAGE/
CEEGOG EX01
A retrospective trial on patients who have undergone salvage surgery for a recurrent uterine or cervical cancer
Salvage database – data from 620 patients collected
Closed

 

 

ENDOMETRIAL Non-commercial trials
Trial Study description Status
TESLA1/
CEEGOG EX-02
Tracers for Endometrial cancer Sentinel node LAbelling
A Prospective observational study on sentinel node biopsy using two concurrent labelling techniques (radioactive tracer with/without blue dye vs. indocyanin green-ICG) in early-stage endometrial cancer patients
The target size of the group: 83 subjects
Ongoing
ENGOT-EN2-DGCG/
EORTC 55102
A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer
The target size of the group: 240 subjects
Enrollment closed

 

 

OVARIAN Commercial trials
Trial Study description Status
AVB500-OC-004/
ENGOT-ov66/GEICO
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
The target size of the group: 300 to 500 subjects
Under preparation
EPIK-O/
ENGOT-ov61/GEICO
A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer
The target size of the group: 358 subjects
Under preparation
MER-XMT-1536-1/
UPLIFT/
ENGOT-ov67/AGO-A
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
The target size of the group: 180 to 240 subjects
Under preparation
BOUQUET/
ENGOT-GYN2/GINECO
A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors
The target size of the group: 80-200 subjects
Ongoing
MK-7339-001-00/
ENGOT-ov43/BGOG
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or
Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
The target size of the group: 1367 subjects
Enrollment closed
INNOVATE-3/
ENGOT-ov50/BGOG
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)
The target size of the group: 540 subjects
Ongoing
FIRST
ENGOT-ov44/GINECO
A Patient‑centric, Randomized, Phase 3 comparison of Platinum‑based Therapy with or without bevacizumab to the same plus TSR‑042 as first‑line treatment of stage iii or iv non-mucinous ovarian cancer followed by maintenaNce therapy
The target size of the group: 720 - 960 subjects
Enrollment closed
ATHENA/
ENGOT-ov45/NCRI
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
The target size of the group: 1000 subjects
Enrollment closed
MIRASOL/
ENGOT-ov55/ BGOG
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
The target size of the group: 430 subjects
Ongoing
SOV09/VITALIA/
ENGOT-ov53/CEEGOG
A phase III, multicentre, randomized, double-blind, placebo-controlled trial of DCVAC/OvCa added to standard of care induction and maintenance therapy in patients with relapsed platinum-sensitive ovarian, fallopian tube, and primary peritoneal carcinoma
The target size of the group: 678 subjects
Preparation terminated
SOTIO/
SOV01
SOV01 A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with newly diagnosed epithelial ovarian carcinoma
The target size of the group: additional 30 subjects
Enrollment closed
SOTIO/
SOV06
SOV06 An open-label, single-group, multicenter phase II clinical trial evaluating the effect of maintenance DCVAC/OvCa after standard of care therapy in women with first relapse of platinum-sensitive epithelial ovarian carcinoma
The target size of the group: 30 subjects
Enrollment closed
IMAGYN050/
YO39523/GOG-3015/
ENGOT-ov39
A phase III, multicenter, randomized study of Atezolizumab versus placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
The target size of the group: 1300 subjects
Enrollment closed
PRIMA/
ENGOT-ov26/GEICO/1509
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Studyof Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
The target size of the group: 620 subjects
Enrollment closed
JAVELIN OVARIAN 200 A phase 3, multicenter, randomized, open-label study of Avelumab (MSB0010718C) alone or in combination with Pegylated liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer
Approximately 550 patients will be randomized
Closed
SOTIO/
SOV02
SOV02 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with relapsed platinum sensitive epithelial ovarian carcinoma Closed
SOTIO/
SOV03
SOV03 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy in women with relapsed platinum resistant epithelial ovarian carcinoma Closed
MILO/
ENGOT-ov11/BGOG
MEK Inhibitor in Low-grade Serous Ovarian Cancer
A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Closed
NOVA/
ENGOT-ov16/NSGO
Niraparib in OVArian cancer
A randomized, double-blind phase 3 trial of maintenance with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer
Closed

 

 

CERVICAL Commercial trials
Trial Study description Status
SENTICOL III/
ENGOT-cx4/GINECO
International validation study of sentinel node biopsy in early cervical cancer
The target size of the group: 950 subjects
Ongoing
BRAVA/
ENGOT-cx17/GINECO
A Phase 3 Trial of Balstilimab versus Investigator Choice Chemotherapy in Patients with Recurrent Cervical Cancer after Platinum-Based Chemotherapy
The target size of the group: 486 subjects
Under preparation
GCT1015-05/
ENGOT-cx8/BGOG
A Phase 2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer
The target size of the group: 140 subjects
Ongoing
GCT1015-07/
ENGOT-cx12/BGOG
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer
The target size of the group: 486 subjects
Under preparation
FERMATA/
ENGOTcx13/AGO
An International Randomized Double-blind Clinical Trial of BCD-100
Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer
The target size of the group: 316 subjects
Preparation terminated
KEYNOTE-A18/
ENGOT-cx11/MITO
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer
The target size of the group: 980 subjects
Ongoing
GCT1015-04/
ENGOT-cx6/BGOG
A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax®‑TF‑ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer
The target size of the group: 100 subjects
Enrollment closed

 

 

ENDOMETRIAL Commercial trials
Trial Study description Status
DUO-E/
ENGOT EN-10/BGOG
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumabwith or without Olaparibin Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer
The target size of the group: 699 subjects
Ongoing
KEYNOTE-B21/ ENGOT-en11/BGOG A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent
The target size of the group: 990 subjects
Ongoing
SIENDO/
ENGOT-EN5/BGOG-EN5
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer.
The target size of the group: 248 subjects
Ongoing
RUBY/
ENGOT EN-6/NSGO
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY)
The target size of the group (PART I): 470 subjects
The target size of the group (PART II): 270 subjects
Ongoing